www.england.nhs.uk/ourwork/pe/cdf/<\/a><\/p> <\/p>
<\/p>
<\/p>
NHS England has published a summary financial report for the Cancer Drugs Fund which states that the Fund was overspent by £30,539,000 in 2013-14. We understand from NHS England that this overspend was not funded from funding for radiotherapy services but from underspends in other parts of NHS England\u2019s budget.<\/p>
<\/p>
<\/p>
<\/p>
Since October 2010, over 55,000 patients in England have benefitted from the Cancer Drugs Fund.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-07T14:49:39.213446Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer Drugs Fund"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, with reference to NHS England's consultation document Proposal for a sustainable Cancer Drug Fund, page 9, Points 24 and 25, what NHS England's overspend of the Cancer Drug Fund (CDF) was during its first year in charge of the CDF; whether the CDF was in budget each year prior to 1 April 2013; how much was taken from the radiotherapy budget to underwrite the overspend; from which disease area money was taken to underwrite the CDF overspend; and how much funding was taken in such a fashion to underwrite the overspend.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4089", "label" : {"_value" : "Biography information for Tessa Munt"}
}
, "tablingMemberConstituency" : {"_value" : "Wells"}
, "tablingMemberPrinted" : [{"_value" : "Tessa Munt"}
], "uin" : "213358"}
, {"_about" : "http://data.parliament.uk/resources/106323", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/106323/answer", "answerText" : {"_value" : "
The Department\u2019s National Institute for Health Research (NIHR) is funding a systematic review of evidence on the benefits, harms and costs of treatments for idiopathic pulmonary fibrosis (IPF). The report is expected to be published in the journal Health Technology Assessment<\/em> in January 2015.<\/p> <\/p>
<\/strong><\/p> <\/p>
The NIHR Clinical Research Network (CRN) provides support to help the life sciences industry set up and deliver large multi-centre clinical trials in the National Health Service, across a wide range of disease and therapeutic areas. The CRN is currently hosting trials assessing the efficacy and safety of lebrikizumab and simtuzumab in patients with IPF. The CRN is also recruiting patients to a pilot study seeking to test whether omeprazole can reduce cough in patients with IPF.<\/p>
<\/p>
<\/strong><\/p> <\/p>
<\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-07T12:09:02.2968024Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Idiopathic Pulmonary Fibrosis"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what steps his Department has taken to act upon the research by the National Institute for Health Research into idiopathic pulmonary fibrosis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1409", "label" : {"_value" : "Biography information for Mr Gregory Campbell"}
}
, "tablingMemberConstituency" : {"_value" : "East Londonderry"}
, "tablingMemberPrinted" : [{"_value" : "Mr Gregory Campbell"}
], "uin" : "213429"}
, {"_about" : "http://data.parliament.uk/resources/106324", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/106324/answer", "answerText" : {"_value" : "
NHS England published a Patient Safety Alert on 20 March 2014 on improving medication error incident reporting and learning. This cited research on medication error rates in medicine, including prescribing error rates of:<\/p>
<\/p>
- 7% of prescription items in hospitals; and<\/p>
<\/p>
- 5% of prescriptions in general practice of which 0.18% were severe errors.<\/p>
<\/p>
<\/p>
<\/p>
There is limited research to quantify actual harm arising from prescribing errors, many of which are picked up by pharmacists at the dispensing stage.<\/p>
<\/p>
<\/p>
<\/p>
Significant investment has been made by the Department, Health Education England and NHS Education for Scotland over the last four years in the development of a National Prescribing Safety Assessment. This is a joint initiative by the Medical Schools Council and the British Pharmacological Society involving the United Kingdom\u2019s leading experts in prescribing, clinical pharmacology and medical assessment. It is intended to enhance patient safety by ensuring that all new graduates entering the first year of Foundation training have achieved a basic standard of practice.<\/p>
<\/p>
<\/p>
<\/p>
It is the Nursing and Midwifery Council\u2019s (NMC) role to ensure that nurse and midwife prescribers provide an appropriate level of treatment and care for their patients. The NMC does this by setting standards to ensure that nurses and midwives are competent to prescribe drugs, and by making sure that their knowledge and skills in prescribing remain up-to-date.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-07", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "213307"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-07T14:48:22.7220747Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-04", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Prescriptions"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, whether his Department has any plans to strengthen the training of (a) clinicians and (b) nurses to reduce prescribing errors.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4056", "label" : {"_value" : "Biography information for Nic Dakin"}
}
, "tablingMemberConstituency" : {"_value" : "Scunthorpe"}
, "tablingMemberPrinted" : [{"_value" : "Nic Dakin"}
], "uin" : "213430"}
, {"_about" : "http://data.parliament.uk/resources/105984", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/105984/answer", "answerText" : {"_value" : "
The main primary care database held by the Clinical Practice Research Datalink (CPRD) is known as CPRD GOLD (formerly known as the General Practice Research Database, or GPRD). CPRD GOLD contains the anonymised, longitudinal medical records of patients registered with contributing primary care practices across the United Kingdom.<\/p>
<\/p>
<\/p>
<\/p>
The CPRD GOLD database covers approximately 8.8% of the UK population, including practices in England, Northern Ireland, Scotland and Wales. As of September 2014 there were 684 general practitioner (GP) practices and 13.58 million acceptable (research quality) patients in GOLD, of which 5.69 million are active (still alive and registered with the GP practice). Data has been collected from GP practices since 1987.<\/p>
<\/p>
<\/p>
<\/p>
A review of the CPRD GOLD database has identified the a total of 15,248 acceptable (research quality) patients with at least one record of pneumococcal disease in CPRD GOLD over the period 1 January 1987 to 30 September 2014 during their up-to-standard registration period. Of these patients, 14,150 had at least one record of pneumococcal pneumonia and 491 patients had at least one record of pneumococcal meningitis.<\/p>
<\/p>
<\/p>
<\/p>
Over the period 1 October 2013 to 30 September 2014, there were a total of 473 acceptable (research quality) patients with at least one record of pneumococcal disease during their up-to-standard registration period. Of these patients; 445 had a record of pneumococcal pneumonia and 14 had at least one record of pneumococcal meningitis.<\/p>
<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-06", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-06T13:15:07.2719615Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-11-03", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pneumococcal Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what proportion of people have records contained in the General Practice Research Database; how many patients whose records are in the Database have at least one record of pneumococcal disease (a) in total and (b) in the last year for which figures are available; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
}
, "tablingMemberConstituency" : {"_value" : "Coventry South"}
, "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
], "uin" : "213015"}
, {"_about" : "http://data.parliament.uk/resources/101761", "AnsweringBody" : [{"_value" : "Department for Business, Innovation and Skills"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/101761/answer", "answerText" : {"_value" : "
There are no published official statistics on the regional distribution of life science industry jobs. The table below includes an estimate of employment in 2013 in companies active in three \u201chealth life science\u201d sectors: Medical Biotechnology, Medical Technology and Pharmaceuticals, by region and by constituent part of the UK, obtained from the Bioscience and Health Technology company database used by the Office for Life Sciences. The figures are based on locations of active sites for which employment figures can be obtained. They do not include those employed by public or third sector organisations nor employment in companies whose main activity falls outside life sciences, including indirect suppliers to the sector.<\/p>
<\/p>
| <\/td> | Number of employees in health life science industry \u2018000s 2013<\/strong><\/p><\/td><\/tr>East Midlands<\/p><\/td> | 9.5<\/p><\/td><\/tr> | East of England<\/p><\/td> | 28.8<\/p><\/td><\/tr> | Greater London<\/p><\/td> | 13.6<\/p><\/td><\/tr> | North East England<\/p><\/td> | 7.1<\/p><\/td><\/tr> | North West England<\/p><\/td> | 17.0<\/p><\/td><\/tr> | South East England<\/p><\/td> | 36.8<\/p><\/td><\/tr> | South West England<\/p><\/td> | 8.2<\/p><\/td><\/tr> | West Midlands<\/p><\/td> | 14.5<\/p><\/td><\/tr> | Yorkshire and the Humber<\/p><\/td> | 13.5<\/p><\/td><\/tr> | England total<\/p><\/td> | 149.0<\/p><\/td><\/tr> | | <\/td> | <\/td><\/tr> | Northern Ireland<\/p><\/td> | 4.3<\/p><\/td><\/tr> | Scotland<\/p><\/td> | 11.5<\/p><\/td><\/tr> | Wales<\/p><\/td> | 9.1<\/p><\/td><\/tr> | UK Total<\/p><\/td> | 173.9<\/p><\/td><\/tr><\/tbody><\/table> Source: Bioscience and Health Technology database, an annual summary of the data was published as \u201cStrength and Opportunity 2013, the landscape of the medical technology, medical biotechnology, industrial biotechnology and pharmaceutical sectors in the UK\u201d<\/p> <\/p> <\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-07", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-07T16:53:00.0739828Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "26"}
, "answeringDeptShortName" : {"_value" : "Business, Innovation and Skills"}
, "answeringDeptSortName" : {"_value" : "Business, Innovation and Skills"}
, "date" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Biotechnology"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Business, Innovation and Skills, what estimate he has made of the number of jobs in each region and constituent part of the UK which are supported by the life science industry.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"}
}
, "tablingMemberConstituency" : {"_value" : "Salisbury"}
, "tablingMemberPrinted" : [{"_value" : "John Glen"}
], "uin" : "212639"}
, {"_about" : "http://data.parliament.uk/resources/101878", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/101878/answer", "answerText" : {"_value" : " Information on the net ingredient cost of mifepristone (RU486) used in National Health Service secondary care in England is shown in the table. This may include use in private wards in NHS hospitals and excludes use in military or private hospitals. Mifepristone is not used in primary care.<\/p> <\/p> <\/p> <\/p> Net ingredient cost of mifepristone in secondary care, England<\/p><\/td><\/tr> | <\/p> Year<\/p><\/td> | Net ingredient cost
£000s<\/p><\/td><\/tr> | 2013<\/p><\/td> | 1,107.8<\/p><\/td><\/tr> | 2012<\/p><\/td> | 1,113.6<\/p><\/td><\/tr> | 2011<\/p><\/td> | 1,153.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> Source:<\/em> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health<\/p> <\/p> <\/strong><\/p> <\/p> <\/strong><\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-06", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-06T13:27:01.8504034Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-30", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Abortion"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on RU486 in each year since January 2011.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1447", "label" : {"_value" : "Biography information for Andrew Rosindell"}
}
, "tablingMemberConstituency" : {"_value" : "Romford"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Rosindell"}
], "uin" : "212552"}
, {"_about" : "http://data.parliament.uk/resources/101563", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/101563/answer", "answerText" : {"_value" : " The New Medicines Fund in Scotland is a matter for the Scottish Government and it would not be appropriate for the Government to comment on its effectiveness or merits.<\/p> <\/p> <\/p> <\/p> In England, in accordance with normal government accounting rules and the agreed 2014 Pharmaceutical Price Regulation Scheme (PPRS), there is no separately identified or ring-fenced funding stream associated with PPRS payments. Nevertheless, the Government can provide an assurance that all PPRS payments received for England will be used for spending on improving patients\u2019 health and care. As part of this, NHS England and the Association of the British Pharmaceutical Industry are pressing ahead with plans to improve access to and optimise the use of medicines to improve patient outcomes.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-11-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-11-05T15:04:30.0669039Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Drugs: Scotland"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the effectiveness and merits of (a) the recently announced New Medicines Fund in Scotland and (b) other funding models aimed at driving improved patient access to innovative medicines in the context of the payments made by the pharmaceutical industry under the current Pharmaceutical Pricing Regulation Scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/1538", "label" : {"_value" : "Biography information for Rosie Cooper"}
}
, "tablingMemberConstituency" : {"_value" : "West Lancashire"}
, "tablingMemberPrinted" : [{"_value" : "Rosie Cooper"}
], "uin" : "212458"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&answer.answeringMember.label=Biography+information+for+George+Freeman&max-answer.dateOfAnswer=2014-11-10", "page" : 0, "startIndex" : 1, "totalResults" : 128, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
| |